Medtronic Announces Major Leadership Restructuring and Plans to Spin Off Diabetes Business

01

Cardiovascular Business Leadership Change

CST Business President Takes Office

Local time5Month21Day，MedtronicAnnounce,Executive Vice President and President of the Cardiovascular PortfolioSean SalmonWill Leave Medtronic，CraniumBrain and SpineTechnology（CST）Senior Vice President and PresidentSkip KiilAppointed as the successor, effective immediately。

Skip KiilWill be submitted toMedtronicCEO Geoff MarthaReport work and become a member of the Medtronic Executive Committee.Original SpineVice President and General ManagerMichael CarterWill replaceKiilServe asCSTSenior Vice President and President。

Geoff MarthaIndicates:“For the cardiovascular business,SkipThe appointment comes at an exciting time. His global mindset and proven track record in commercialization and market development，Will support the strong cardiovascular team to further advance the impact and momentum of these exciting therapies.”

In the latest earnings season, Medtronic announced several major pieces of news.

In addition to cardiovascular andCraniumBrain and SpineTechnologyIn addition to personnel changes in the department, Medtronic also stated,ProposedDiabetes BusinessSplitFor the new independent listed company。（Just Now! Medtronic Announces Split）

About the CompanyDiabetes BusinessThe news of the split had been rumored before. In the latest press release, Medtronic confirmed this news and stated,Executive Vice President and President of Medtronic Diabetes BusinessQue DallaraWill Serve as CEO of New Diabetes Company。

This spin-off is expected to enable the newTheDiabetes companies can focus more on investing in their product lines, as well as manufacturing scale and automation, enabling them to excel in automated insulin delivery and smart multiple daily injection systems (MDI) achieve success in, while expanding profit margins over time.

In terms of management arrangements this monthMedtronicStillAnnouncement，Will be handled byKate CroninServe as the Chief Marketing Officer of the diabetes business. Earlier this year, a former senior executive of Dexcom.Laura EndresBecame the new head of Medtronic's Diabetes Business Unit in the Americas.Both have rich experience in the medical field.

On the issue of tariffs,Medtronic Predicts，2026Annual cost of sales will be affected by approximately2Hundreds of millions to3.5Billion-Dollar Tariff Impact。

Will Focus on Innovation-Driven Growth

Cardiac Ablation Q4 Grows Nearly 30%

5Month21Day, MedtronicPublished as of2025Year4Month25The Fourth Quarter of the Day (Q4) and2025Fiscal Year (FY25) Financial performance.

Among which, the fourth quarter revenue89Billion USD, year-on-year growth3.9%`, Organic Growth`5.4%; Operating profit is14Billion USD, Growth36%。2025Fiscal Year Revenue335Billion USD, reported growth3.6%`, Organic Growth`4.9%; Operating Profit60Billion USD, year-on-year growth16%。

(Screenshot from Medtronic's financial report) 

Looking at the细分 business,DiabetesBusiness2025Fiscal Year Revenue27.55Billion US dollars,OrganicGrowth11.5%。

Currently MedtronicDiabetesThe momentum of business growth across its segmentsIn the leading group, with a significant gap in scale compared to other sectors.2025Fiscal Year,Diabetes business accounts for Medtronic's revenue8%，Accounting for the operating profit of Medtronic's department4%。

Currently, the diabetes market, especially the CGM sector, is experiencing strong growth, driving the increase of related companies and products.

Medtronic's flagship product is making good progress.MiniMed™780GAutomatic Insulin Delivery (AID) The continuous adoption of the system, andMiniMed™780GThe increase in the installed base andCGMThe strong momentum has enabled MedtronicQ4 U.S. revenue achieved high single-digit growth. As users upgrade toSimplera Sync™ Sensors, Pumps andThe growth of CGM drove the increase in international revenue in Q4.

This Year4Month, Medtronic announced,FDA alsoApprovedSimplera Sync™SensorUsed forMiniMed™780GSystem,Will be2025Limited release in the United States in the fallThis is expected to further drive the growth of the U.S. market.

According to the previous plan,Advanced Collaboration with AbbottCGMProduct Portfolio Update, alsoExpected to2025The second half of the year in the United StatesFDASubmit。

Relatively speaking, the market and audience characteristics faced by Medtronic's diabetes business differ from those of the traditional medical market. After taking separate paths, both will focus more on their respective business areas.

Medtronic stated,NewTheDiabetes Company will be a leading, scaledDirect-to-ConsumerDiabetes Enterprises. While the spun-off MedtronicWillMore focused on innovation-driven growth and taking the lead in the medical system and among doctor customers.。

Among the other three major departments,Cardiac and Vascular Business2025Fiscal year revenue is124.81USD billion, organic growth6.3%. Heart Rhythm and Heart FailureCRHF, Structural Heart and AortaSH&AHigh single-digit organic growth, coronary and peripheral vascularCPVLow single-digit organic growth.

Among them, based onPulseSelect™ andAffera™ Localization and Ablation System withSphere-9™PFARapid application of catheters,Cardiac ablation solutions achieved nearly in the fourth quarter30%Growth。

Neuroscience Business2025Fiscal Year Revenue98.46Billion USD, Organic Growth5.2%. Among them,Neuromodulation Growth10.7%, Q4 performance was also above market level. With the adoptionBrainSense™ Technologypercepept™RCDeep Brain Stimulator (DBS) Continuous launch,Brain ModulationAchieved mid-single-digit growth globally.

This Year2Month,Medtronic announcesItsBrainSenseAdaptive Deep Brain Stimulation (aDBS) Platform ObtainedFDAApproval, mainlyFor the treatment of Parkinson's disease, a further step in the brain-computer interface field。

HealthcareSurgeryBusiness2025Fiscal year revenue is84.07Hundred MillionUSD,Organic Growth0.8%. This segment currently shows the weakest growth among Medtronic's four major divisions and ranks third in terms of revenue volume. Among this, the Acute Care and Monitoring businessQ4Performance has improved.

In addition,2025The First Quarter, MedtronicTo the United StatesFDASubmittedHugo™RASSystem for Urological Indications。

In the future, Medtronic will...Focus on areas with the highest profit margins and strongest growth momentum. This global deviceTOPClass enterprises, have spared no effort and are moving forward towards a new round of growth.

END